pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,040 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT786Endpoints593BioPharma Dive228onclive165Fierce Biotech64BioSpace63raps25
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • <![CDATA[Tirabrutinib and CAR T-Cell Therapy Represent Potential Paradigm Shifts in R/R PCNSL ]]>
    <![CDATA[Ashley Sumrall, MD, FACP, FASCO, discusses emerging data for tirabrutinib and the evolving role of CAR T-cell therapy in primary central nervous system lymphoma.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Future Directions in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono conclude the discussion by reflecting on the evolving future of radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mC…
    onclive · 2mo ago↗ source
  • <![CDATA[Personalized Treatment Decision-Making in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Johann De Bono and Dr. Pedro Barata discuss the increasing complexity of personalized treatment decision-making in metastatic castration-resistant prostate cancer (mCRPC) as radiopharm…
← prev
page 29 of 42
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
onclive · 2mo ago↗ source
  • STAT+: What the Trump administration wants in its next FDA leader
    Leaders want the next FDA commissioner to be someone who can rebuild trust, focus on food policy, and drive drug-approval reforms.
    STAT · 2mo ago↗ source
  • <![CDATA[Future Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss the future direction of radiopharmaceutical therapies and emerging treatment strategies in metastatic castration-resistant prostate cancer (…
    onclive · 2mo ago↗ source
  • <![CDATA[Safety and Toxicity Management in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Johann De Bono and Dr. Pedro Barata discuss practical approaches to monitoring and managing toxicities associated with radiopharmaceutical therapies in metastatic castration-resistant…
    onclive · 2mo ago↗ source
  • <![CDATA[Combination and Sequencing Strategies in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss ongoing questions surrounding combination approaches and optimal sequencing strategies for radiopharmaceutical therapies in metastatic castr…
    onclive · 2mo ago↗ source
  • <![CDATA[Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of treatment sequencing and patient selection for radiopharmaceuticals in metastatic castration-resistant prostate cancer…
    onclive · 2mo ago↗ source
  • <![CDATA[Patient Selection for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss how patient selection and disease characteristics influence the use of radiopharmaceuticals in metastatic castration-resistant prostate canc…
    onclive · 2mo ago↗ source
  • <![CDATA[Alpha-Emitting Therapies in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of alpha-emitting radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mCRPC), with a focus o…
    onclive · 2mo ago↗ source
  • <![CDATA[Consensus Recommendations Address Key Controversies in Lymphoma Management]]>
    <![CDATA[Alexey Danilov, MD, PhD, and Tycel Phillips, MD, highlight key consensus viewpoints in lymphoma published from the 2025 Bridging the Gaps meeting.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Combination Radiopharmaceutical Approaches in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss emerging combination strategies involving radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC), with a focus on t…
    onclive · 2mo ago↗ source
  • <![CDATA[Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono open the discussion by reviewing the evolving role of radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC) and outlining…
    onclive · 2mo ago↗ source
  • U.S. overdose deaths fell again in 2025, but some worry about policy and drug supply changes
    About 70,000 Americans died of drug overdoses last year — about 14% fewer than the previous year, according to preliminary government data.
    STAT · 2mo ago↗ source
  • <![CDATA[Dr Bockorny on the Rationale for Targeting CCR8 in Solid Tumors ]]>
    <![CDATA[Bruno B. Bockorny, MD, discusses the rationale for evaluating the anti-CCR8 antibody in a phase 1 trial in solid tumors. ]]>
    onclive · 2mo ago↗ source
  • Medicare halts enrollment of new hospice, home health providers
    The Centers for Medicare and Medicaid Services said it will pause the enrollment of new hospice and home health providers.
    STAT · 2mo ago↗ source
  • <![CDATA[Answering Key Clinical Questions About Esophageal Cancer Care: With Peter Enzinger, MD ]]>
    <![CDATA[Peter Enzinger, MD, answers common questions about the diagnosis and management of esophageal cancer in this clinician-focused FAQ interview.]]>
    onclive · 2mo ago↗ source
  • The ‘velocity of obesity’ aims to show which nations are slowing an epidemic
    A study finds the rise in U.S. obesity rates have hit a plateau in children but are still climbing for adults, and are still high compared to those in other…
    STAT · 2mo ago↗ source
  • <![CDATA[FDA Approval Insights: Brexu-Cel for Relapsed/Refractory MCL: With Luhua (Michael) Wang, MD]]>
    <![CDATA[Luhua (Michael) Wang, MD, discusses the implications of the FDA approval of brexu-cel for the treatment of adult patients with relapsed/refractory MCL. ]]>
    onclive · 2mo ago↗ source
  • New subpoena suggests DOJ has begun criminal investigation of gender-affirming care
    Several hospitals have received federal grand jury subpoenas regarding gender-affirming care for minors, suggesting a criminal investigation has begun.
    STAT · 2mo ago↗ source
  • STAT+: Gene therapy viruses linked to a boy’s tumor
    The case for Makary as the WOAT, Cassidy's seat at risk ahead of midterms, and other biotech news from The Readout
    STAT · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more
    FDA Commissioner Marty Makary is resigning, and Kyle Diamantas, the agency's top food regulator, will step in as acting commissioner
    STAT · 2mo ago↗ source
  • STAT+: AI medical devices’ dirty FDA secret
    In this edition of STAT's AI Prognosis newsletter: A look at the quirks of the most common FDA medical device approval pathway, sepsis algorithms, and more.
    STAT · 2mo ago↗ source
  • <![CDATA[UCSF Receives Major Gift to Advance Research and Modernization]]>
    <![CDATA[Kathy Chiao and Ken Hao commit $100 million for major capital projects, cancer research, and innovation at UCSF — building on a recent $75 million gift to UC Davis for veterinary medicine.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer]]>
    <![CDATA[The panel surveys the clinical trial landscape and emerging therapeutic strategies for patients with recurrent endometrial cancer, particularly those who have progressed on frontline check…
    onclive · 2mo ago↗ source